Bioconjugate Chemistry · 2017 · 52 citations · 21 references
MedicineNuclear MedicineOncologyMolecular ImagingOncologic Nuclear MedicineTherapeutic Nuclear MedicinePositron Emission TomographyProstate Cancer ImagingProstate ImagingRadiopharmaceutical DesignTargeted Imaging AgentsTumor ImagingAzide-alkyne Cycloaddition ProbesMolecular Imaging Probe DesignPsma-pet ImagingRadiopharmaceutical ImagingRadiopharmaceutical UptakeTumor Radiotracer ImagingTumor Uptake KineticsTumor Uptake Mechanisms
68 Ga-Glu-urea-Lys-(Ahx)-HBED-CC ( 68 Ga-PSMA-11) represents a successful radiopharmaceutical for PET/CT imaging of prostate cancer. Further optimization of the tumor-to-background contrast might significantly enhance the sensitivity of PET/CT imaging and the probability of detecting recurrent prostate cancer at low PSA values. This study describes the advantage of histidine (H)/glutamic acid (E) and tryptophan (W)/glutamic acid (E) containing linkers on the pharmacokinetic properties of 68 Ga-PSMA-11. The tracers were obtained by a combination of standard Fmoc-based solid-phase synthesis and copper(I)-catalyzed azide–alkyne cycloaddition. Their 68 Ga complexes were compared to the clinical reference 68 Ga-PSMA-11 with respect to cell binding, effective internalization, and tumor targeting properties in LNCaP-bearing balb/c nu/nu mice. The introduction of (HE) i ( i = 1–3) or (WE) i ( i = 1–3) into PSMA-11 resulted in a significantly changed biodistribution profile. The uptake values in kidneys, spleen, liver, and other background organs were reduced for (HE) 3 while the tumor uptake was not affected. For (HE) 1 the tumor uptake was significantly increased. The introduction of tryptophan-containing linkers also modulated the organ distribution profile. The results clearly indicate that histidine is of essential impact in order to improve the tumor-to-organ contrast. Hence, the histidine/glutamic acid linker modifications considerably improved the pharmacokinetic properties of 68 Ga-PSMA-11 leading to a reduced uptake in dose limiting organs and a significantly enhanced tumor-to-background contrast. Glu-urea-Lys-(HE) 3 -HBED-CC represents a promising 68 Ga complex ligand for PET/CT-imaging of prostate cancer.
21
Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 974 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Ali Afshar‐Oromieh, Christian M. Zechmann, A. Malcher et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 928 citations · Full text
Martina Benešová, Martin Schäfer, Ulrike Bauder‐Wüst et al. · Journal of Nuclear Medicine · 2015 · 594 citations
Joshua James Morigi, Phillip D. Stricker, Pim J. van Leeuwen et al. · Journal of Nuclear Medicine · 2015 · 567 citations · Full text
Medicine, Nuclear Medicine, Oncology +17